Knowledge Base | FAQ

New Jersey Drug and Alcohol Inpatient Treatment Licensing

New Jersey state flag

Written by

A. Ant, CADC-II

in

Author: A. Ant, CADC-II, Licensing & Accreditation Expert

Disclaimer: This content is provided for general informational purposes only and should not be construed as legal, regulatory, or licensing advice. Requirements change frequently. Consult qualified professionals for guidance specific to your situation.

Apply now: DOH Certificate of Need and Licensing (CN&L) | Questions: cnandlicensingrequests@doh.nj.gov

Residential substance use disorder treatment in New Jersey is licensed under N.J.A.C. 8:111 (formerly 10:161A) by the Department of Health, Division of Certificate of Need and Licensing (CN&L), not by DMHAS, a distinction a surprising amount of guidance still gets wrong.

DOH Licenses the Facility, DMHAS Does Not

Mixing up these two agencies can waste weeks before anything is filed. The licensing authority moved in two steps. Reorganization Plan No. 001-2017 (effective August 28, 2017) shifted the Division of Mental Health and Addiction Services (DMHAS), together with its licensing and inspection duties, from the Department of Human Services to DOH. Plan No. 001-2018 (effective August 20, 2018) sent DMHAS back to Human Services but kept facility licensing and inspection at DOH. DMHAS is still SAMHSA’s designated Single State Agency for substance use, with policy authority and funding for community services, but the facility license itself comes from DOH’s CN&L. Filing with the wrong agency, or assuming DMHAS reviews the application, is a common mistake that stalls residential projects.

Certificate of Need: Ask Before You Assume

We could not find a New Jersey statute or rule that requires a Certificate of Need for residential substance use disorder beds, and several primary sources point the other way. DOH’s Certificate of Need page lists psychiatric beds, rehabilitation beds and long-term care among the projects needing full review, with no SUD bed category. N.J.A.C. 8:111 conditions approval on substantial compliance plus written local zoning, fire, health and building approvals, with no CN step, and the chapter rests on N.J.S.A. 26:2B-14 and 26:2G-23 rather than the CN statute. DOH’s 2017 SUD application form even carried a “New Facility – CN Exempt (N.J.S.A. 26:2H-7a)” box. Our reading is that a freestanding residential SUD program generally does not need a CN. Because the same CN&L division handles both programs, get its answer in writing before you sign a lease, and treat any plan that adds psychiatric beds separately, since those sit on the full-review list.

Residential Treatment Sits Outside the New Integrated Outpatient License

This new structure doesn’t actually touch residential programs, even though it’s easy to assume otherwise. New Jersey’s new integrated license, N.J.A.C. 8:43K, effective April 6, 2026, lets one license cover mental health, substance use disorder, opioid treatment, and primary care services together, but only for outpatient and integrated care facilities. Residential SUD treatment stays under its own chapter, N.J.A.C. 8:111, because the scope section of 8:43K reaches only entities seeking licensure as an outpatient or integrated care facility.

Where CARF’s ASAM Level of Care Certification Fits

N.J.A.C. 8:111 sorts residential programs by facility type and ties each one to an ASAM placement level: halfway houses approximate Level III.1, extended care facilities III.3, long-term residential facilities III.5, short-term residential facilities III.7, and non-hospital medical detoxification III.7D. The DOH license names the facility type. It is not an ASAM certification. CARF offers a separate ASAM Level of Care Certification, which ASAM delivers in partnership with CARF, for adult residential Levels 3.1, 3.5 and 3.7. Lined up against New Jersey’s categories (our own comparison, since neither CARF nor DOH publishes one), that covers halfway house, long-term residential and short-term residential programs. Extended care at III.3 falls outside it, and so does the III.7D detox level, so a program offering withdrawal management cannot use the certification to vouch for that service. Certified programs can be looked up in CARF’s provider search with the “ASAM Level of Care 3.7” filter (3.1 and 3.5 have their own filters), which gives referral sources and payers something they can check without taking your word for it.

Medication for Opioid Use Disorder in a Residential Setting

Methadone treatment runs through an opioid treatment program, and New Jersey now licenses OTPs under N.J.A.C. 8:43K (DOH’s proposal gave them subchapter 8), a different license from the N.J.A.C. 8:111 residential license this guide covers. A residential facility without OTP licensure needs a real coordination agreement with a licensed OTP that covers transport and dose continuity. Name the specific partner in that agreement rather than leaning on a general referral statement, and check the partner’s federal certification in SAMHSA’s Opioid Treatment Program Directory before you sign. Buprenorphine is simpler. DEA’s January 12, 2023 letter to registrants ended the DATA waiver, so a prescriber now needs only a standard DEA registration number. N.J.A.C. 8:111 also carries its own appendices with guidelines for buprenorphine products and for injectable naltrexone, which your medication policies should track.

Adding Ketamine Under an N.J.A.C. 8:111 License

New Jersey’s residential rules never mention ketamine, and DOH has not ruled on it. What follows applies the licensing, nursing, pharmacy and practice rules we cite below to a ketamine service, so read the conclusions as our interpretation and get CN&L’s answer in writing.

One sentence in the licensing subchapter decides how careful you need to be. N.J.A.C. 8:111-2.1(l) says the license specifies the services the facility may provide, and that “any provision of services not specifically listed on the license shall be considered unlicensed provision of services.” A ketamine series for a resident’s co-occurring depression or PTSD is a medical treatment rather than a new level of care, so it may sit inside the medical services a short-term or detox facility already has to provide on site. We still would not guess. Ask CN&L whether the addition needs a license modification before the first dose. If it does, the 8:111-2.1 fee schedule lists $500 for a modification to add beds or services.

The medical structure is already written into the rule. Detoxification and short-term residential facilities must render medical services on site, and they, along with long-term facilities, designate a medical director “who shall supervise the medical services provided” (8:111-7.1). Long-term facilities can bring physicians in through written agreements instead. Nursing is thinner than many operators expect: short-term and long-term programs need one registered nurse on duty eight hours a day, Monday through Friday, with an RN on call the rest of the time (8:111-8.1). Schedule dosing for weekday hours when the RN is actually in the building. Orders must be signed and dated by the prescriber, and 8:111-14.2 requires a verifiable record system for controlled medication and points to the pharmacy board’s storage rules in N.J.A.C. 13:39.

State and Federal Registrations

Ketamine is a Schedule III controlled substance (21 CFR 1308.13(c)(7)), and New Jersey layers its own registration on top of DEA’s. The Division of Consumer Affairs requires a New Jersey CDS registration for controlled substance activity in the state, a separate one at any additional location where you keep a stock of CDS, and an address on the state registration that matches the DEA registration. Prescription monitoring is lighter than for opioids. N.J.S.A. 45:1-46.1 requires a PMP lookup for a non-opioid, non-benzodiazepine Schedule III or IV drug only when the prescriber reasonably believes the patient may be seeking it for non-medical purposes, and it exempts a practitioner administering a CDS directly to the patient. In an addiction treatment population we would run the lookup anyway and note it in the chart.

If the program prefers esketamine nasal spray, Spravato is available only through the Spravato REMS. It can be given only in a healthcare setting certified in that program, and the patient has to be monitored for at least two hours after each dose, per the FDA-approved medication guide. We found no New Jersey Board of Nursing statement on RN-administered ketamine, so the medical director’s written protocol carries most of the weight. Advanced practice nurses prescribe controlled substances under joint protocols with a collaborating physician, and N.J.S.A. 45:11-49 requires those protocols to say whether the APN must consult the physician before starting a controlled drug. Write ketamine into the protocol by name.

Which Residents Are Candidates

Ketamine is not FDA-approved for any substance use disorder, so it is not MOUD and it does nothing to replace the OTP and buprenorphine pathway described above. Where it can earn a place is a depressive or PTSD picture that is still there once withdrawal is over and the usual medications have been tried. Our admissions screen would include a direct question about dissociative and hallucinogen use, and a yes generally takes ketamine off the table for that resident.

After Discharge: Who Can Own the Follow-On Clinic

Starting a series in residential care gives the team days of observation that no outpatient office gets. Most responders will want to keep going after they leave, which usually means an outpatient ketamine practice, and New Jersey is strict about who owns one. The Board of Medical Examiners rule on practice structure, N.J.A.C. 13:35-6.16(e), says a health care service “shall be owned solely by one or more licensed health care professionals,” and a general business corporation can contract with the practice only for services “exclusively of a non-professional nature,” with the licensee keeping sole discretion over patient fees (6.16(f)5). So the workable shape is a management services company paired with a practice owned by New Jersey licensees. The details are in the ketamine section of New Jersey Drug and Alcohol Outpatient Treatment Licensing.

Referrals between the two need a lawyer’s eye. The federal Eliminating Kickbacks in Recovery Act (18 U.S.C. § 220) makes it a crime to pay or receive remuneration for referrals to a licensed SUD treatment setting, which includes the residential program itself, and 13:35-6.16(e) requires a physician who refers patients to an entity where the physician holds a significant beneficial interest to document the clinical justification and stay within the exceptions in N.J.S.A. 45:9-22.4.

Staffing a Residential Program

New Jersey’s CADC-to-LCADC pipeline is the real lever operators have on residential payroll. N.J.A.C. 8:111-1.8 requires every facility to have a director of substance abuse counseling services. An LCADC with a clinical master’s degree is one qualifying route, but a licensed psychologist, clinical social worker, professional counselor or marriage and family therapist can also hold the job, and most routes call for five years of addiction work, two of them supervisory. The state’s median wage for substance abuse, behavioral disorder, and mental health counselors is $64,710 a year (BLS OEWS, May 2024), against roughly $59,350 nationally, so a residential program with a clinical director, several counselors, and 24-hour direct-care staff commonly runs well past $450,000 a year in payroll before nursing coverage. The counselor rules leave operators some room on that figure. Under 8:111-1.9, half the counseling staff must be LCADCs, CADCs or other licensed clinical professionals, while the other half can be counselor-interns working toward a credential for up to three years. CADCs (certified by the State Board of Marriage and Family Therapy Examiners on the Alcohol and Drug Counselor Committee’s recommendation) work under an LCADC or another New Jersey licensed clinician and may not diagnose, so leaning on them for counseling roles trims payroll and still gives newer staff a ladder to climb. Nursing follows the same logic: 8:111-1.5 requires a registered nurse as director of nursing and reserves nursing assessments for RNs, which is why many programs pair one RN with several LPNs rather than putting a registered nurse on every shift. That specific staffing matrix comes together once census and level of care are confirmed.

How to Submit Your DOH Application

Start with CN&L’s Intake Unit (609-376-7800, cnandlicensingrequests@doh.nj.gov) and ask for the current residential application. N.J.A.C. 8:111-2.1 calls for a completed application and fee for each site. DOH’s current Form CN-7, Application for New or Amended Acute Care Facility License (its revision line reads “AUG 24”), lists “Residential Substance Abuse Treatment Facility” among its inpatient facility types and asks for filing 45 days before the planned opening. The fee under 8:111-2.1 is $500 plus $3 per bed for a new license and the same for each renewal, which comes every year because the license runs one year (12 consecutive months), and a licensed facility also pays a $500 biennial inspection fee. Approval under 8:111-2.5 turns on substantial compliance with the chapter and written approvals from the local zoning, fire, health and building authorities, and no client may be admitted before DOH issues the license. The rule does not list a document packet for that filing, but 8:111-2.5(d) bases approval partly on your description of the physical plant, finances and hiring practices, and DOH schedules its survey once you report the building is ready for occupancy, so have the policy and procedure manual that 8:111-3.6 calls for finished by then. CN&L reviews it, not DMHAS.

What Delays New Jersey Residential Applications

Two issues account for most of the delays we see on these applications. The most common is filing with, or waiting on review from, DMHAS when DOH’s CN&L actually controls the facility license. The second is leaving local sign-offs for last. DOH cannot approve the license without written approvals from local zoning, fire, health and building officials, and each of those offices keeps its own calendar.

Frequently Asked Questions

How long does it take to open a residential SUD program in New Jersey?

Plan for roughly 12 to 20 months from planning to a DOH license. That range is our own estimate, not a state figure, and most of the swing comes from site work, local zoning, fire, health and building approvals, and the DOH licensing review itself.

Does DMHAS license residential SUD facilities in New Jersey?

No. Reorganization Plan No. 001-2017 moved facility licensing to DOH, and the 2018 plan kept it there when DMHAS went back to Human Services. DMHAS keeps policy and funding authority, but DOH’s Division of Certificate of Need and Licensing issues the facility license.

Does a Certificate of Need apply to a new residential SUD facility?

We have not found a primary source that requires one. DOH’s Certificate of Need full-review list names psychiatric beds but no substance use disorder bed category, and N.J.A.C. 8:111 has no CN step in its licensing rules. Get DOH’s Division of Certificate of Need and Licensing to confirm your project’s status in writing before committing capital, especially if the plan includes psychiatric beds.

Want your New Jersey residential SUD filing in front of CN&L right the first time? Reach out here.

Sources

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

More posts

Top